Literature DB >> 15352991

Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack.

Dominick J H McCabe1, Paul Harrison, Paul S Sidhu, Martin M Brown, Samuel J Machin.   

Abstract

The percentage of reticulated platelets (% RP) could be a useful marker of increased platelet production and/or turnover in patients with increased platelet activation, but few flow cytometric studies have measured the % RP in patients with ischaemic cerebrovascular disease (CVD). Whole blood flow cytometry using thiazole orange was performed to compare the % RP in patients in the early (1-27 d, n = 79) and late phases (79-725 d, n = 70) after ischaemic stroke or transient ischaemic attack (TIA) with controls without CVD (n = 27). The impact of aspirin dose escalation (75-300 mg/d) on the % RP was investigated in 10 patients in the late phase after stroke/TIA. The platelet count and mean platelet volume (MPV) were similar in CVD patients and controls. Compared with controls, the unadjusted % RP was not significantly higher in early or late phase CVD patients (P < or = 0.3). However, having adjusted for age, the % RP was higher in early (P = 0.047) and late phase CVD patients (P = 0.01). There was a positive correlation between % RP and MPV in EDTA- and citrate-anticoagulated blood in both early and late phase CVD patients (P< or = 0.01). The % RP was not significantly influenced by aspirin dose. These data do not convincingly support an excessive stimulus to platelet production in the early or late phases after ischaemic stroke/TIA, but are consistent with the hypothesis that reticulated platelets are larger than more mature 'non-reticulated' platelets in ischaemic CVD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15352991     DOI: 10.1111/j.1365-2141.2004.05137.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  19 in total

1.  Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness.

Authors:  Homam Ibrahim; Srinivas Nadipalli; Timothy DeLao; Sasidhar Guthikonda; Neal S Kleiman
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

2.  Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes.

Authors:  Monica Verdoia; Chiara Sartori; Patrizia Pergolini; Matteo Nardin; Roberta Rolla; Lucia Barbieri; Alon Schaffer; Paolo Marino; Giorgio Bellomo; Harry Suryapranata; Giuseppe De Luca
Journal:  J Thromb Thrombolysis       Date:  2016-05       Impact factor: 2.300

3.  Platelet-large cell ratio and the extent of coronary artery disease: results from a large prospective study.

Authors:  Giuseppe De Luca; Matteo Santagostino; Gioel Gabrio Secco; Ettore Cassetti; Livio Giuliani; Lorenzo Coppo; Alon Schaffer; Angelica Fundaliotis; Sergio Iorio; Luca Venegoni; Giorgio Bellomo; Paolo Marino
Journal:  J Thromb Thrombolysis       Date:  2010-11       Impact factor: 2.300

4.  Mean platelet volume and mortality risk in a national incident hemodialysis cohort.

Authors:  Steven Kim; Miklos Z Molnar; Gregg C Fonarow; Elani Streja; Jiaxi Wang; Daniel L Gillen; Rajnish Mehrotra; Steven M Brunelli; Csaba P Kovesdy; Kamyar Kalantar-Zadeh; Connie M Rhee
Journal:  Int J Cardiol       Date:  2016-06-23       Impact factor: 4.164

5.  Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.

Authors:  W O Tobin; J A Kinsella; G F Kavanagh; J S O'Donnell; R T McGrath; T Coughlan; D R Collins; D O'Neill; B Egan; S Tierney; T M Feeley; R P Murphy; D J H McCabe
Journal:  J Neurol       Date:  2014-04-30       Impact factor: 4.849

6.  Adenosine and blood platelets.

Authors:  Hillary A Johnston-Cox; Katya Ravid
Journal:  Purinergic Signal       Date:  2011-02-08       Impact factor: 3.765

7.  Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication.

Authors:  Constance C F M J Baaten; Leo F Veenstra; Rick Wetzels; Johanna P van Geffen; Frauke Swieringa; Susanne M de Witt; Yvonne M C Henskens; Harry Crijns; Sven Nylander; J J J van Giezen; Johan W M Heemskerk; Paola E J van der Meijden
Journal:  Haematologica       Date:  2015-06-25       Impact factor: 9.941

8.  Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor.

Authors:  Alon Eisen; Hila Lerman-Shivek; Leor Perl; Eldad Rechavia; Dorit Leshem-Lev; Noa Zemer-Wassercug; Oshrat Dadush; Shirit Kazum; Pablo Codner; Ran Kornowski; Eli I Lev
Journal:  J Thromb Thrombolysis       Date:  2015-07       Impact factor: 2.300

9.  Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.

Authors:  W O Tobin; J A Kinsella; G F Kavanagh; J S O'Donnell; R A McGrath; D R Collins; T Coughlan; D O'Neill; B Egan; S Tierney; T M Feeley; R P Murphy; Dominick J H McCabe
Journal:  J Neurol       Date:  2012-10-14       Impact factor: 4.849

10.  Mean platelet volume is decreased in HIV-infected women.

Authors:  S Qadri; S Holman; J Dehovitz; H Crystal; H Minkoff; J M Lazar
Journal:  HIV Med       Date:  2013-06-05       Impact factor: 3.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.